Results 231 to 240 of about 2,542,433 (345)

The Carnivorous and Herbivorous Types in Man [PDF]

, 1916
John P. Bryant
openalex   +1 more source

TRPM8 levels determine tumor vulnerability to channel agonists

Molecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, Nicole Annesi, Sacha Genovesi, Annalisa Lorenzato, Karen Widmann, Michela Libergoli, Elisa Marmocchi, Giovanni Bertalot, Alberto Brolese, Mauro Giulio Papotti, Luca Molinaro, Orazio Caffo, Mattia Barbareschi, Alberto Bardelli, Alessandro Romanel, Sabrina Arena, Andrea Lunardi   +18 more
wiley   +1 more source

Combination of Cpb-Hsp70 typing methods reveals genetic divergence between Leishmania infantum strains causing human tegumentary leishmaniasis in northern Italy and central Spain: a retrospective study. [PDF]

Infect Dis Poverty
Gritti T, Chicharro C, Carrillo E, Solana JC, Moreno J, Carra E, Ortalli M, Morselli S, Gaspari V, Zanazzi M, Lazzarotto T, Rugna G, Varani S.   +12 more
europepmc   +1 more source

A Postscript on the Terminology of Types [PDF]

, 1897
F. A. Bather
openalex   +1 more source

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer

Molecular Oncology, EarlyView.
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine, Sterenn Guillemot, Louis‐Bastien Weiswald, Romane Florent, Edwige Abeilard, Florence Giffard, Emilie Brotin, Mélanie Briand, Enora Dolivet, Laurent Poulain, Marie Villedieu   +10 more
wiley   +1 more source

Cervical EVT isolation for non-invasive fetal HLA typing in early pregnancy is limited by purity and maternal cell contamination; a methodological comparison. [PDF]

Front Immunol
van 't Hof LJ, Kapsenberg JM, Drabbels JJM, van der Meeren LE, Roelen DL, Eikmans M, van der Hoorn MP.   +6 more
europepmc   +1 more source

The Type Locality of Ortalis V. Vetula: A Correction [PDF]

, 1921
Ludlow Griscom
openalex   +1 more source

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

Molecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte, Osheen Sharma, Laura Leuenberger, Emelie Wallin, Josefin Fernebro, Päivi Östling, Rebecka Bergström, Johan Lindberg, Ulrika Joneborg, Olli Kallioniemi, Brinton Seashore‐Ludlow   +10 more
wiley   +1 more source

Value of collaborative investigation by hospital infection control, public health services and a national reference laboratory during an increase in puerperal sepsis. [PDF]

Antimicrob Resist Infect Control
Hoogendijk IV, de Zwart-Slats D, Boers SA, van der Putten BCL, van Sorge NM, Molenaar BDH, Toorop MMA, Veenhof MB, Veldkamp KE, van der Schoor AS, van Prehn J.   +10 more
europepmc   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source